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S U M M A R Y
The respiratory ﬂuoroquinolones moxiﬂoxacin, gemiﬂoxacin, and high-dose levoﬂoxacin are recom-
mended in guidelines for effective empirical antimicrobial therapy of community-acquired pneumonia
(CAP). The use of these antibiotics for this indication in areas with a high prevalence of tuberculosis (TB)
has been questioned due to the perception that they contribute both to delays in the diagnosis of
pulmonary TB and to the emergence of ﬂuoroquinolone-resistant strains of Mycobacterium tuberculosis.
In this review, we consider some of the important questions regarding the potential use of
ﬂuoroquinolones for the treatment of CAP where the burden of TB is high. The evidence suggests
that the use of ﬂuoroquinolones as recommended for 5–10 days as empirical treatment for CAP,
according to current clinical management guidelines, is appropriate even in TB-endemic regions. It is
critical to quickly exclude M. tuberculosis as a cause of CAP using the most rapid relevant diagnostic
investigations in the management of all patients with CAP.
 2013 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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The respiratory ﬂuoroquinolones moxiﬂoxacin, gemiﬂoxacin,
and levoﬂoxacin (at a daily dose of 750 mg) are recommended for
empirical antimicrobial therapy of community-acquired pneumo-
nia (CAP).1,2 Despite their proven worth in CAP, it has been
suggested that ﬂuoroquinolone use should be restricted to the
management of tuberculosis (TB), even though there have been
few well-controlled clinical studies of their use in TB-endemic
parts of the world.3–6 More speciﬁcally, some authors have
proposed that newer ﬂuoroquinolones should not be used in
areas of TB endemicity, given the potential to mask active TB and
the threat of an emerging epidemic of ﬂuoroquinolone- and
extensively drug-resistant (XDR) TB.7,8* Corresponding author. Tel.: +1 905 828 5168; fax: +1 905 828 0113.
E-mail address: RGrossman@cvh.on.ca (R.F. Grossman).
1201-9712  2013 The Authors. Published by Elsevier Ltd on behalf of International S
http://dx.doi.org/10.1016/j.ijid.2013.09.013In this review, we examine the role of respiratory ﬂuoroqui-
nolones in the treatment of both TB and CAP and consider how
these agents should be used in the context of both infections.
2. Fluoroquinolone treatment in the management of CAP
CAP may be caused by a wide variety of pathogens, but a limited
number of agents are responsible for most cases. Recent data have
conﬁrmed Streptococcus pneumoniae to be the most common
pathogen isolated from patients with CAP.1,2 Other bacterial causes
include non-typeable Haemophilus inﬂuenzae and Moraxella catar-
rhalis, generally in patients with underlying bronchopulmonary
disease, Staphylococcus aureus, especially during an inﬂuenza
outbreak, and so-called ‘atypical’ organisms, such as Mycoplasma
pneumoniae, Chlamydophila pneumoniae, Legionella species, and
respiratory viruses.1,9
There is good pharmacological and clinical evidence to
support the use of respiratory ﬂuoroquinolones in CAP. Their
favourable pharmacokinetic and pharmacodynamic proﬁles result
in good penetration of respiratory tissues; the administration of a
single 400-mg oral dose of moxiﬂoxacin, for example, achieves
higher concentrations in alveolar macrophages (56.7 mg/ml) andociety for Infectious Diseases. Open access under CC BY-NC-ND license.
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The broad antibacterial activity of respiratory ﬂuoroquinolones
provides excellent coverage of the major CAP-causing pathogens,
including penicillin- and macrolide-resistant S. pneumoniae.11
Dosing is once daily and the availability of oral and intravenous
formulations of moxiﬂoxacin and levoﬂoxacin allows delivery of
effective therapy to a wide range of patients, including the
critically ill.2 Ineffective initial therapy of CAP is the most
signiﬁcant prognostic and single intervention-related factor linked
to mortality.12 A meta-analysis of 15 clinical trials showed that
pneumonia was cured or improved in signiﬁcantly more patients
treated with ﬂuoroquinolones than those treated with macrolide 
beta-lactam antibiotics.13 Moxiﬂoxacin monotherapy, for example,
has been shown to be superior to amoxicillin–clavulanic acid 
clarithromycin in terms of clinical cure and bacteriological success in
the treatment of patients hospitalized with CAP.14 Fluoroquinolones
were also more effective than macrolides  beta-lactams for patients
with severe pneumonia, those who were hospitalized and those who
required intravenous therapy.13
Fluoroquinolones are generally recommended in different
management guidelines for use in CAP, i.e., pneumonia in
immunocompetent subjects arising outside of the hospital. The
Infectious Diseases Society of America (IDSA) and the American
Thoracic Society (ATS) consensus guidelines, for example, recom-
mend monotherapy with a respiratory ﬂuoroquinolone for patients
with CAP admitted to general medical wards, or a combination of a
beta-lactam and a respiratory ﬂuoroquinolone for patients admitted
to intensive care units (ICUs) and who do not have risk factors for
methicillin-resistant S. aureus or Pseudomonas spp.1 The European
Respiratory Society (ERS) and European Society for Clinical
Microbiology and Infectious Diseases (ESCMID) guidelines recom-
mend a ﬂuoroquinolone as: (1) ﬁrst-line monotherapy for hospital-
ized (non-ICU) patients with CAP; (2) monotherapy or in
combination with a non-antipseudomonal cephalosporin for
patients with severe CAP in the ICU or intermediate care; and (3)
second-choice agent for the treatment of CAP in outpatients.2 In the
treatment of patients hospitalized with CAP with guideline-
concordant antibiotic regimens, ﬂuoroquinolone monotherapy is
as effective as macrolide/beta-lactam combinations.15 Importantly,
non-adherence to CAP treatment guidelines is a signiﬁcant risk
factor for treatment failure and mortality.16
An assessment of existing national guidelines for the treatment
of lower respiratory tract infections (LRTIs) and/or CAP in Europe
was recently conducted by questionnaire sent to ERS national
delegates.17 The survey revealed that 18 of 24 responding
delegates had national or regional guidelines for the management
of CAP, and of those, seven guidelines included recommendations
on the differential diagnosis, treatment, and management of TB.
Seven responders also conﬁrmed that their guidelines included
recommendations on the use of ﬂuoroquinolones in CAP and the
risk of selecting ﬂuoroquinolone-resistant M. tuberculosis in
misdiagnosed patients. In several countries in Europe with low
TB incidence, opportunities for physicians to investigate a TB
patient are relatively rare and so there is a risk that TB is not
considered as a potential diagnosis when a patient with an LRTI
presents for consultation. Revision of national and regional
guidelines for the management of LRTIs and/or CAP is therefore
warranted, speciﬁcally to describe the need to consider the
differential diagnosis of TB and highlight the potential risk of
fostering ﬂuoroquinolone resistance in TB patients who are
misdiagnosed and do not receive appropriate therapy.
3. Diagnosis of CAP
Data from clinical studies illustrate that the differential
diagnosis of TB from bacterial pneumonia is not straightforward.In Asian countries, 1–7% of cases presenting as CAP were re-
diagnosed as pulmonary TB.18 Most of these patients were over 65
years of age with various comorbidities.18 In contrast, studies in
Africa have identiﬁed M. tuberculosis as the cause of pneumonia in
approximately 30% of HIV-infected patients,19,20 indicating a shift
in the aetiology of pneumonia in severely ill patients immuno-
compromised with advanced HIV.
In the absence of a diagnostic ‘gold standard’, the diagnosis of
CAP is based on demonstration of a new inﬁltrate on chest
radiograph or other imaging technique in the presence of recently
acquired respiratory signs and symptoms. Chest radiography of
patients with cough and fever lasting 2–3 days due to bacterial
pneumonia reveals an airspace inﬁltrate, in clear contrast to the
cavitating lung lesions seen in patients with a history of cough for 3
months or longer accompanied by weight loss, which are typical of
TB. Clinical ﬁndings do not, however, reliably predict radiologically
conﬁrmed pneumonia,21 as features of TB may sometimes be quite
similar to those of CAP among patients who experience symptoms
at the early stage. In addition, the etiology cannot be simply
differentiated clinically or radiologically and is undeﬁned in
approximately 50% of patients.
The presence of HIV inﬂuences the presentation of pulmonary
infections and so complicates the diagnosis of CAP and TB,
particularly in areas of high TB prevalence. In HIV-positive
patients, lung characteristics identiﬁed by chest X-ray or
computed tomography imaging together with clinical course
(acute vs. chronic onset) can be helpful in suggesting the etiology.
This has enabled an algorithm approach to the evaluation of
hospitalized HIV-seropositive patients with suspected CAP to be
recommended.22
4. Fluoroquinolone treatment for TB
Fluoroquinolones have considerable potential to treat TB due to
their favourable pharmacokinetics and activity against the target
pathogen. Later-generation ﬂuoroquinolones including gatiﬂox-
acin, levoﬂoxacin (750 mg/day), moxiﬂoxacin (maximum 400 mg/
day), and even oﬂoxacin, are suggested by the World Health
Organization (WHO) as second-line anti-TB agents.23 However,
none is licensed for use in the treatment of drug-susceptible TB,
and these should only be used for the treatment of multidrug-
resistant TB (MDR-TB),24 or when toxicity curtails the use of
standard anti-TB therapy. Earlier ﬂuoroquinolones (sparﬂoxacin
and ciproﬂoxacin) have also been evaluated in some clinical trials,
but are not generally considered effective as second-line agents.
Ciproﬂoxacin should not be used.25While some small studies have
indicated the efﬁcacy of ﬂuoroquinolones in TB,3–6 no large-scale
controlled clinical trial has been completed. In addition, these
drugs are intended and approved for short-term use and safety
data are lacking for their long-term use.
Moxiﬂoxacin 400 mg is currently being tested in two phase III
multicentre international clinical trials: the Rapid Evaluation of
Moxiﬂoxacin in the treatment of sputum smear positive Tubercu-
losis (REMoxTB) study and the International Multicentre Con-
trolled Clinical Trial to Evaluate High Dose Rifapentine and a
Quinolone in the Treatment of Pulmonary Tuberculosis (RIFA-
QUIN). Both studies are investigating the possibility of shortening
chemotherapy from 6 to 4 months, which is expected to
substantially improve treatment completion rates and adherence.
In the REMoxTB study, one group is given 6 months of standard
treatment, a second group receives moxiﬂoxacin substituted for
ethambutol as part of a 4-month regimen, and a third group receives
moxiﬂoxacin substituted for isoniazid as part of a 4-month
regimen.26,27 In the now completed RIFAQUIN study,28 three drug
combination regimens were compared. The 6-month control
standard regimen contained rifampin, isoniazid, ethambutol, and
Figure 1. Cumulative percentage of patients becoming afebrile during treatment for
tuberculosis. (Reprinted with permission of the American Thoracic Society.
Copyright  2013 American Thoracic Society. Kiblawi SS, et al. Fever response of
patients on therapy for pulmonary tuberculosis. Am Rev Respir Dis 1981;123:20–4.
Ofﬁcial journal of the American Thoracic Society.).
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months and contained rifampin, moxiﬂoxacin, rifapentine, etham-
butol, and pyrazinamide given daily in a 2-month intensive phase.
The study results will demonstrate whether the new regimens
(containing moxiﬂoxacin) for 6 months or 4 months were non-
inferior to standard therapy. A 4-month regimen containing
gatiﬂoxacin is also being tested in a different phase II clinical trial
in ﬁve African countries. The test treatment comprises the standard
combination of drugs with gatiﬂoxacin in place of ethambutol
administered daily for 2 months. During the continuation phase,
patients will receive weekly treatment with gatiﬂoxacin, rifampin,
and isoniazid for 2 months.29
5. Use of ﬂuoroquinolones in CAP in TB-endemic areas: current
issues
Empiric treatment of CAP in areas with high TB prevalence has
raised some questions regarding the use of ﬂuoroquinolones:
(1) Among patients with an LRTI, does ﬂuoroquinolone treatment
delay the diagnosis of pulmonary TB?
(2) If a patient with subsequently diagnosed TB improves rapidly
with ﬂuoroquinolone treatment, is the improvement truly an
improvement of TB or resolution of a concurrent bacterial
respiratory tract infection?
(3) Is the eventual diagnosis of TB delayed?
(4) If a delay in diagnosis occurs, does this affect outcome and is it
speciﬁcally related to the use of ﬂuoroquinolones?
(5) Is the use of ﬂuoroquinolones associated with a higher
frequency of culture-negative TB?
(6) If ﬂuoroquinolones are used to treat LRTIs, does this induce
ﬂuoroquinolone resistance in M. tuberculosis isolates?
(7) If so, what is the scale of exposure required?
(8) What is the impact of the use of respiratory ﬂuoroquinolones in
the treatment of TB or CAP on the development of resistance in
organisms other than M. tuberculosis (e.g., S. pneumoniae,
Enterobacteriaceae)?
6. Clinical differentiation of CAP from TB
Comparing the typical clinical courses of CAP and TB provides
some useful points of difference. For example, in a prospective
observational study of time-to-clinical stability in patients
hospitalized with CAP, fever was resolved (highest temperature
for the day 37.8 8C) in a median of 3 days (interquartile (IQR)
range 2–4 days).30–32 In comparison, a study of patients with
pulmonary TB who received appropriate multidrug anti-TB
therapy found that fever resolved after a mean of 16 days
(Figure 1). An important caveat to this observation is that
antimicrobial treatment of a presumed co-existing bacterial
infection did not inﬂuence the course of fever.33
In two-thirds of patients with bacterial pneumonia, radiological
evidence of pulmonary inﬁltrates is absent 4 weeks after
diagnosis.34 Although radiographic monitoring of the response
during TB treatment is not recommended,35 radiography can be
expected to show positive changes within 1 month and resolving
or becoming stable in 90% of patients by 6 months.36 Conversely, a
small proportion of patients with TB can have progressive
pulmonary inﬁltrates despite evidence of clinical improvement
in response to appropriate antibiotic therapy.37
Clinical features predictive of pulmonary TB were identiﬁed in a
prospective study in which M. tuberculosis was isolated from 4.9%
of patients hospitalized for CAP. The presence of symptoms lasting
more than 2 weeks prior to admission, upper lobe involvement or
cavitary inﬁltrates on chest radiograph, total white blood cell count
12  109/l on admission, night sweats, and lymphopenia were allsigniﬁcantly associated with culture-positive pulmonary TB.38
Identiﬁcation of these features at presentation clearly strengthens
the diagnostic suspicion of TB, and sputa should be submitted for
smear and culture analysis.
Taken together, these ﬁndings indicate that if a patient with
symptoms of pneumonia responds quickly to antimicrobial
therapy, they are likely to have a bacterial pneumonia. In contrast,
TB is not associated with a rapid response to treatment even when
treated with appropriate multidrug regimens.
6.1. Laboratory tests to differentiate CAP from TB
The tuberculin skin test (TST) has been the standard immuno-
diagnostic test for TB for over a century and is still widely used in
screening to detect the immune response to mycobacterial
antigens, but is not useful as a method to diagnose the disease.
The overall sensitivity of the TST has been estimated as 77% in a
meta-analysis,39 but the sensitivity can be substantially impaired
by a variety of factors. In particular, the speciﬁcity of the TST is
dependent on the Bacillus Calmette–Gue´rin vaccination status40
and the immune status of the person being tested.39 In the context
of differentiating CAP and TB, the TST lacks the required sensitivity
and speciﬁcity and is not recommended.41
Interferon gamma (IFN-g) release assays (IGRAs), which
measure T-cell release of IFN-g in response to M. tuberculosis-
speciﬁc antigens, have high sensitivity for active TB, superior to
that of the TST. However, the speciﬁcity of IGRAs is poor in patients
with suspected active TB in high TB burden settings, suggesting
they are of limited use as a conﬁrmatory test for active TB in TB-
endemic countries with a high background prevalence of latent
TB.42 A WHO Expert Group has discouraged the use of IGRAs for the
diagnosis of active pulmonary TB in low- and middle-income
countries.43
In resource-limited settings, TB diagnosis typically relies on
the identiﬁcation of acid-fast bacilli (AFB) on unprocessed
sputum smears using conventional light microscopy. This
approach has proved highly speciﬁc for pulmonary TB due to
M. tuberculosis in high TB incidence areas. The overall sensitivity
of sputum-based diagnosis is 20–80%,44 and is highest for
patients with cavitary disease and lowest in patients with weak
cough or less advanced disease.44 Diagnosis requires a concen-
tration of bacilli of 5000–10 000/ml for a trained and skilled
technician to detect 1–3 organisms in 300 oil immersion ﬁelds.
The overall yield for smear and culture is superior with multiple
specimens. Compared with conventional light microscopy,
ﬂuorescence microscopy is more sensitive and has similar
Figure 2. Time to tuberculosis treatment from initial contact with healthcare
services by antibiotic type. (Reprinted with permission of the International Union
Against Tuberculosis and Lung Disease. Copyright  The Union. Wang M, et al. Is the
delay in diagnosis of pulmonary tuberculosis related to exposure to
ﬂuoroquinolones or any antibiotic? Int J Tuberc Lung Dis 2011;15:1062–8.).
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establish the diagnosis by culture in HIV-positive patients, a
minimum of two smears is needed to achieve an acceptable early
diagnostic yield.46 Repeated sputum induction considerably
improves diagnostic accuracy.47 Bronchoscopy is useful for
patients with radiographic features consistent with TB but who
have smear-negative sputum or produce no sputum.48
Nucleic acid ampliﬁcation assays should be used to conﬁrm the
presence of M. tuberculosis following a smear test positive for AFB.
The Xpert MTB/RIF assay (Cepheid Inc., Sunnyvale, CA, USA) can
accurately detect TB and rifampin resistance in less than 2 h. The
WHO-endorsed assay is a fully integrated and automated system
that is simple to perform and requires minimal training and
laboratory facilities. Studies have shown it to be sensitive and
speciﬁc,49 superior to AFB smear microscopy,50,51 with high
sensitivity in smear-negative TB51 and effective for the early
and accurate diagnosis of TB and MDR-TB in low-resource, TB-
endemic settings.52
The low levels of serum C-reactive protein (CRP) and
procalcitonin (PCT) found in patients with pulmonary TB provide
useful discrimination between those with bacterial CAP, including
HIV-positive patients, and those with pneumonia caused by
Pneumocystis jirovecii infection.53–56 A recent study in Korea, an
intermediate TB-burden country, found the neutrophil–lympho-
cyte count ratio (NLR) to be signiﬁcantly lower in patients with
pulmonary TB than in those with bacterial CAP, and to provide
superior diagnostic discrimination of the two diagnoses than
CRP.57
The detection of M. tuberculosis antigens in urine represents an
important potential approach for the diagnosis of TB in resource-
limited settings. However, this method is not currently accepted as
a gold standard in many low income countries. The lipoarabino-
mannan urinary assay shows most promise, but has suboptimal
sensitivity for routine clinical use.58 However, positive urinary
antigen tests for pneumococcal and Legionella antigens allow early
exclusion of TB.
7. Does ﬂuoroquinolone treatment extend the delay to
diagnosis that commonly occurs in cases of pulmonary TB?
Delay in TB diagnosis can either be patient delay or healthcare
system delay. Patient delay refers to the time from onset of clinical
symptoms to the ﬁrst visit to a healthcare centre, while healthcare
system delay is the time from ﬁrst patient visit to a healthcare
centre to establishment of a TB diagnosis.59 An average patient
delay of 4 weeks and an average healthcare system delay of 3–5
weeks are common.59 Even in hospitalized patients with smear-
positive disease, delays in the suspicion and treatment of TB are
common, with one study ﬁnding overall management delays of
more than 10 days occurring in a third of patients.60
Several studies have investigated the inﬂuence of empirical
antibiotic treatment for respiratory infection on the period from
presentation to diagnosis of TB. A small retrospective cohort study
in Baltimore, USA, showed a longer median time (16 days, p = 0.04)
between presentation and treatment of pulmonary TB in patients
prescribed ﬂuoroquinolones compared with those who received
non-ﬂuoroquinolone antibiotics.61 A similar result was reported
from a randomized open-label study in Hong Kong, although
paradoxically the study data showed that of those patients who
developed active pulmonary TB during a 1-year follow-up, 4.8%
were given amoxicillin–clavulanate and 1.4% were given moxi-
ﬂoxacin.62 A retrospective study in Taiwan identiﬁed longer
duration from initial visit and from mycobacterial culture
sampling to the start of anti-TB treatment in patients with
conﬁrmed TB who had received empirical therapy with ﬂuor-
oquinolones. However, the patients’ age, higher prevalence ofconstitutional symptoms and malnourishment, and lower fre-
quency of AFB-positive sputum tests, suggest that the different
clinical presentation of these patients probably contributed to the
different course of diagnosis and treatment.63
A meta-analysis of four studies61,63–65 showed a mean duration
of delayed diagnosis and treatment of pulmonary TB of 19 days in
patients prescribed ﬂuoroquinolones compared with those who
received non-ﬂuoroquinolone antibiotics. This analysis also
showed, however, that the initiation of anti-TB antibiotics was
not delayed in patients prescribed ﬂuoroquinolones. Although
intended to investigate the effect of prior antibiotic treatment for
CAP, patients in the studies included those who had received
ﬂuoroquinolones for a variety of non-respiratory infections,
including urinary tract infections and wound infections.66
The ﬁndings of a single, large, population-based study in British
Columbia provide clearer evidence that healthcare delays with
pulmonary TB patients occur following treatment with any
antibiotic, not just with a ﬂuoroquinolone67 (Figure 2). Using
the linked health databases of the province, this study collected
data for 2232 patients who had active TB between 1997 and 2006.
After excluding incomplete patient records, data were analyzed for
1544 patients with antibiotic exposure within 6 months prior to
the initiation of anti-TB treatment, 414 of whom (27%) received
antibiotics, while the remaining 1130 (73%) did not. Antibiotic-
treated patients experienced on average more than twice the
healthcare delay compared with the non-antibiotic group, after
adjusting for covariates; the median healthcare delay was 41 days
(IQR 15–86) for the antibiotic group compared with 14 days (IQR
3–44) for the non-antibiotic group (adjusted risk ratio (RR) 2.12,
95% conﬁdence interval (CI) 1.82–2.46). When stratiﬁed by type of
antibiotic use, there was no difference in the delay in diagnosis of
TB between those who received non-ﬂuoroquinolone antibiotics
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Figure 3. Percent ﬂuoroquinolone resistance according to duration of
ﬂuoroquinolone exposure (10 days vs. >10 days) and timing of last exposure
(60 days vs. >60 days) before tuberculosis diagnosis. (A) No outpatient
ﬂuoroquinolone exposure (n = 524). (B) 10 days of ﬂuoroquinolones and last
ﬂuoroquinolone exposure 60 days before tuberculosis diagnosis (n = 34). (C) 10
days of ﬂuoroquinolones and last ﬂuoroquinolone exposure >60 days before
tuberculosis diagnosis (n = 28). (D) >10 days of ﬂuoroquinolones and last
ﬂuoroquinolone exposure 60 days before tuberculosis diagnosis (n = 30). (E)
>10 days of ﬂuoroquinolones and last ﬂuoroquinolone exposure >60 days before
tuberculosis diagnosis (n = 24). (Reprinted with permission of the American
Thoracic Society. Copyright  2013 American Thoracic Society. Devasia RA, et al.
Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration
and timing of ﬂuoroquinolone exposure. Am J Respir Crit Care Med 2009;180:365–
70. Ofﬁcial journal of the American Thoracic Society.).
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(adjusted RR 2.18, 95% CI 1.42–3.32), and mixed ﬂuoroquinolone
and non-ﬂuoroquinolone (adjusted RR 2.37, 95% CI 1.86–3.03)
(Figure 2). Increased treatment delays were also related to the
number of courses of antibiotics prescribed. These data suggest
that the delay in initiating anti-TB treatment is more probably a
result of diagnostic doubt. Consistent with this, Golub et al.64 also
found that diagnostic delays were associated with all classes of
antibiotics prescribed and noted that when a physician considered
the possibility of TB (e.g., requesting a sputum smear and
mycobacterial culture, or receiving a radiograph report suggesting
TB), antibiotics were less likely to be prescribed. Similarly, a UK
study that found longer times to diagnosis of TB with prior
antibiotic treatment revealed that the delay appeared to be a
consequence of prolongation of the healthcare process and was not
predicted by symptomatic improvement.68 This suggests that a
delayed diagnosis of TB may not be due to the anti-TB activity of
ﬂuoroquinolones, but rather the time inherent in taking a course of
antibiotics and waiting to see if there is a clinical response. In
contrast, Jeon et al.69 reported that TB patients exposed to a
ﬂuoroquinolone for 5 days or more before sputum collection were
more likely to be smear-negative than unexposed patients, and
that this was likely to be mediated by the antibacterial effect of
ﬂuoroquinolones. However, ﬂuoroquinolone use is not associated
with an increased risk of culture-negative TB.70
8. Development of ﬂuoroquinolone resistance in M.
tuberculosis
The cellular target of ﬂuoroquinolones in M. tuberculosis is DNA
gyrase, a tetrameric type II topoisomerase composed of two A and
two B subunits encoded by the gyrA gene and gyrB gene,
respectively.71
Unlike many bacterial species, M. tuberculosis appears to lack
topoisomerase IV, a cellular protein also inhibited by ﬂuoroqui-
nolones, and DNA gyrase appears to be the sole target for
ﬂuoroquinolone antibiotics.72 Genetic resistance to an anti-TB
drug is caused by spontaneous chromosomal mutations at a
frequency of 106 to 108 mycobacterial replications. Mobile
genetic elements such as plasmids and transposons, known to
mediate drug resistance in various bacterial species, do not cause
mutations in M. tuberculosis.73
Fluoroquinolone resistance in M. tuberculosis is mainly due to
the acquisition of point mutations within a conserved region of
gyrA (320 bp) and gyrB (375 bp), the quinolone resistance-
determining region (QRDR). Mutations within the QRDR of gyrA
account for 42–100% of ﬂuoroquinolone resistance in M. tubercu-
losis, with codons 90, 91, and 94 being the most mutated sites.73
Resistance due to gyrB mutations was thought to be rare, but
clinical isolates resistant to ﬂuoroquinolones with gyrB mutations
and wild-type gyrA loci have recently been reported in several
studies.74 In addition, the M. tuberculosis pentapeptide repeat
protein MfpA mediates ﬂuoroquinolone resistance by interacting
with DNA gyrase and protecting it from antibiotic binding.75 The
contribution of MfpA expression and other mechanisms potential-
ly responsible for clinical resistance of M. tuberculosis to
ﬂuoroquinolones, such as decreased cell wall permeability, drug
efﬂux pump, drug sequestration, or drug inactivation, requires
clariﬁcation.73
The emergence of MDR and XDR strains of M. tuberculosis
reﬂects multiple aspects of inadequate TB management, including
poor supervision of anti-TB treatment; the misuse of isoniazid and
rifampin, for example, has been widespread.76 The effectiveness of
standard TB therapy can be compromised by several factors,
including poor adherence associated with adverse events and long
duration of treatment, or inadequate drug levels for other reasons(e.g., drug–drug interactions, poor quality medicines, use of over-
the-counter antibiotics). These factors increase the risk of
unsuccessful treatment outcomes and the development of drug
resistance to one or more of the drugs in the regimen.77,78 With
isoniazid monotherapy, for example, the emergence of resistance
in M. tuberculosis is uncommon during the ﬁrst 3 months of
treatment, but more frequent with continuing monotherapy.79
An early study in New York City identiﬁed 22 patients with
ﬂuoroquinolone-resistant M. tuberculosis, 16 of whom had received
ciproﬂoxacin or oﬂoxacin. The median (range) time between
isolation of a ﬂuoroquinolone-susceptible strain and a ﬂuoroquin-
olone-resistant strain was 137 (43–398) days after a period of
ﬂuoroquinolone treatment of 64 (23–271) days,80 far longer than
the recommended treatment course for CAP. Fluoroquinolone
resistance in two of 55 patients with TB (4%) was reported by a
small US study. Both patients had had ﬂuoroquinolone treatment
within the previous 3 months; both were also HIV-seropositive
with low CD4+ lymphocyte counts, reﬂecting poor immunity.71
Important insights into the prevalence of and risk factors for
ﬂuoroquinolone resistance in M. tuberculosis were reported by a
study in Tennessee, USA.81 Of 1136 culture-conﬁrmed cases, 640
had isolates available for ﬂuoroquinolone susceptibility testing;
those with ﬂuoroquinolone-resistant isolates were compared with
those with susceptible isolates. Of the 640 study patients, 116
(18%) had received ﬂuoroquinolones as outpatients before the
diagnosis of TB and 54 (8.4%) had received ﬂuoroquinolones for
more than 10 days. Sixteen patients (2.5%) had ﬂuoroquinolone-
resistant M. tuberculosis isolates. Regression analyses revealed that
>10 days ﬂuoroquinolone exposure was associated with ﬂuoro-
quinolone-resistant TB, while age, gender, race, and HIV serostatus
were not associated with ﬂuoroquinolone resistance. In addition,
patients receiving more than one course of ﬂuoroquinolone
treatment were more likely to have ﬂuoroquinolone-resistant TB
than those who received only one course (p = 0.007). Assessment of
the duration and timing of the last ﬂuoroquinolone exposure
showed that patients receiving ﬂuoroquinolone therapy of 10
days duration more than 60 days before the diagnosis of TB had the
highest proportion (20.8%) of ﬂuoroquinolone-resistant TB
(Figure 3).
R.F. Grossman et al. / International Journal of Infectious Diseases 18 (2014) 14–21 19In a case–control study in Canada, Long et al.82 found that
multiple but not single prescriptions of ﬂuoroquinolones were
associated with ﬂuoroquinolone-resistant TB. This association was
also true for M. tuberculosis strains resistant to ﬁrst-line anti-TB
treatment. Three strains of M. tuberculosis isolated from cases had
increased MICs for ciproﬂoxacin, levoﬂoxacin, and oﬂoxacin,
although only one strain had a resistance-conferring gyrA
mutation. These three strains were isolated from patients who
had received multiple ciproﬂoxacin treatments.82 Similarly, a
retrospective study in South Africa found that one of 201
genotyped M. tuberculosis isolates harboured a resistance-confer-
ring gyrA mutation. This isolate was obtained from a patient who
had been exposed to a total of 8 days of ﬂuoroquinolone treatment
given over three different intervals before culture collection: 1 day
of ciproﬂoxacin 79 days prior, 2 days of oﬂoxacin 42 days prior, and
5 days of ciproﬂoxacin 5 days prior.69
Park et al.83 reported the frequencies of oﬂoxacin resistance as
1.1% in patients with no recent exposure to ﬂuoroquinolones and
8.5% in those who received ﬂuoroquinolone monotherapy within
the previous 3 months. Oﬂoxacin resistance usually accompanied
multidrug resistance. In this study of 2788 Korean patients from
1997 to 2005, the median (range) duration of ﬂuoroquinolone
treatment was 7 days (1–47 days) and 35 of 39 patients received at
least 5 days of ﬂuoroquinolone therapy before M. tuberculosis
culture was performed.83 In contrast, a study in Taiwan found that
neither the previous use of ﬂuoroquinolones nor the duration of
ﬂuoroquinolone exposure was correlated with the ﬂuoroquinolone
susceptibility of M. tuberculosis isolates, 3.3% of which were
ﬂuoroquinolone-resistant.84 However, this study of patients in
tertiary care did not have access to data on previous medication
history, including prior ﬂuoroquinolone use, outside the hospital.
Resistance to ﬂuoroquinolones was also correlated with prior anti-
TB treatment and with resistance to any ﬁrst-line anti-TB drug
(isoniazid, rifampin, and ethambutol).
The association between higher rates of ﬂuoroquinolone
resistance amongst MDR M. tuberculosis strains compared with
susceptible strains is supported by a recent analysis of the
frequency of and risk factors for acquired resistance to second-line
drugs using data from the US National Tuberculosis Surveillance
System 1993–2008. This analysis identiﬁed MDR-TB at treatment
initiation as the only predictor for acquired resistance to
ﬂuoroquinolones (oﬂoxacin or ciproﬂoxacin).85
The clinical data reviewed above strongly suggest that
ﬂuoroquinolone resistance in TB requires repeated and/or pro-
longed courses of monotherapy and is associated with the
presence of MDR rather than previous ﬂuoroquinolone exposure.
In addition to the delay in TB diagnosis and risk of ﬂuoroquin-
olone resistance, the risk of mortality may also be inﬂuenced by a
previous course of ﬂuoroquinolone treatment for patients in areas
where TB is not highly endemic.86 A study by van der Heijden et al.
showed an increased risk of mortality (OR 1.82) if patients were
exposed to ﬂuoroquinolones (ciproﬂoxacin, levoﬂoxacin, or moxi-
ﬂoxacin) before a correct diagnosis of TB. However, the association
between ﬂuoroquinolone exposure and mortality was not present
without adjusting for comorbidities such as chronic obstructive
pulmonary disease, diabetes mellitus, or alcoholism, and when
patients with unknown HIV status were excluded from the
analysis.86
9. Conclusions
The use of ﬂuoroquinolones for 5–10 days as empirical
treatment for CAP, according to current clinical management
guidelines, is appropriate even in regions endemic for TB. However,
indiscriminate use of ﬂuoroquinolones in suspected CAP should be
avoided, and critical judgement on the possibility of TB must takeplace when patients with LRTIs visit respiratory physicians. TB
should always be considered by the physician as a possible cause of
pneumonia, however, and if suspected, the relevant diagnostic
tests should be completed rapidly before prescribing CAP-directed
antibiotics. Empiric antibiotic treatment for suspected CAP (e.g.,
ﬂuoroquinolone monotherapy) should not be started for patients
with a protracted LRTI associated with cough, fever, and weight
loss together with cavitary lung lesions without ﬁrst excluding TB.
Earlier-generation ﬂuoroquinolones such as ciproﬂoxacin and
oﬂoxacin should be avoided for both CAP and TB, as they have
lower activity against both S. pneumoniae and M. tuberculosis.
Similarly, if a patient with symptoms of pneumonia does not
respond to a short course of empiric antibiotic therapy, that
therapy should not be continued and further pathologies, including
possible TB, should be investigated; prolonged and/or repeated
courses of ﬂuoroquinolone monotherapy may be associated with
the emergence of ﬂuoroquinolone resistance in M. tuberculosis and/
or increased mortality. In patients with LRTIs who subsequently
develop TB, empiric therapy with any antibiotic can delay the
diagnosis of TB. However, delays in the diagnosis of TB are
common, even without empiric antibiotic treatment, including
ﬂuoroquinolones. This reﬂects the diagnostic doubt often inherent
in such cases. Fluoroquinolones are important drugs for the
treatment of MDR-TB but should not be used in susceptible disease
until the results of ongoing clinical trials are available or in the case
of drug toxicity.
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